Matthew Herper

Matthew Herper is a senior writer at STAT, where he covers medicine and oversees the editorial portion of STAT's events. He has over 18 years of experience in reporting on medical innovation, writing about various medicines and profiling key figures in the industry. His work has appeared in Forbes, where he covered topics ranging from blockbuster drugs like Lipitor to controversies involving individuals such as Martin Shkreli and Bill Gates.

Biography:  https://www.statnews.com/staff/matthew-herper/

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

98%

Examples:

  • Matthew Herper has a history of covering medical innovation with a focus on medicines and profiling influential figures in the industry. He has reported on both the positive aspects of treatments as well as their potential risks and controversies.

Conflicts of Interest

98%

Examples:

  • Herper has not disclosed any significant conflicts of interest in his articles.

Contradictions

100%

Examples:

  • No contradictions were found in Matthew Herper's articles.

Deceptions

98%

Examples:

  • In one article, Herper highlighted the benefits of a new screening test for colorectal cancer but also included quotes from experts who raised concerns about its potential limitations and the importance of colonoscopy as an alternative.

Recent Articles

FDA Approves First Blood Test, Shield, as Primary Screening Option for Colon and Rectal Cancers: A New Convenient Tool to Detect CRC Early

FDA Approves First Blood Test, Shield, as Primary Screening Option for Colon and Rectal Cancers: A New Convenient Tool to Detect CRC Early

Broke On: Monday, 29 July 2024 The FDA approves Guardant Health's Shield blood test as a primary screening option for colorectal cancer in adults over 45, marking the first approval of its kind. With an 83% sensitivity rate and potential accessibility advantages over colonoscopies, the Shield test could encourage more people to get screened for this second deadliest cancer in the US.
New Studies Suggest HPV Vaccine Reduces Head and Neck Cancers in Men: Significant Decrease in Throat and Mouth Cancer Risk

New Studies Suggest HPV Vaccine Reduces Head and Neck Cancers in Men: Significant Decrease in Throat and Mouth Cancer Risk

Broke On: Thursday, 16 May 2024 New studies reveal that the HPV vaccine not only prevents cervical cancer in women but also reduces head and neck cancer risk in men, as it protects against strains linked to various types of cancer. The HPV vaccine has significantly reduced cervical cancer rates and shows increasing vaccination rates among males, lagging behind females. More research is needed to understand its long-term effects and potential benefits.

FDA Approves Eli Lilly's Omvoh for Ulcerative Colitis Treatment

Broke On: Thursday, 26 October 2023 The FDA has approved Eli Lilly's Omvoh for the treatment of adults with moderate to severe ulcerative colitis. The approval is based on the results of a Phase 3 clinical trial, LUCENT-1, which showed that Omvoh significantly improved clinical remission and endoscopic response rates compared to placebo. Omvoh comes with a boxed warning about the risk of serious infections, malignancies, and a rare but serious condition that affects the brain.

AstraZeneca Seeks FDA Approval for Self-Administration of FluMist Vaccine

Broke On: Tuesday, 24 October 2023 AstraZeneca has submitted a request to the FDA to allow adults to self-administer its annual flu vaccine, FluMist. The company's request is based on data from a study that demonstrated the safety and efficacy of self-administration of FluMist.